Needham Reiterates Buy on Sarepta Therapeutics, Maintains $166 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a $166 price target.

May 02, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Sarepta Therapeutics with a $166 price target.
The reiteration of a Buy rating and maintenance of a $166 price target by a reputable analyst like Gil Blum from Needham is likely to instill confidence among investors and could positively influence Sarepta Therapeutics' stock price in the short term. Analyst ratings, especially with a high price target, often lead to increased investor interest and can drive up the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100